Skip to main content
Premium Trial:

Request an Annual Quote

BioNanomatrix Lands $5.1M in Venture Financing

NEW YORK (GenomeWeb News) – DNA analysis firm BioNanomatrix has secured $5.1 million in series A venture financing, lead investor Battelle Ventures said today.
BioNanomatrix is developing nanoscale single-molecule imaging and analytic platforms with applications in genome analysis and clinical diagnostics. 
The funding round included an investment from Battelle’s affiliate Innovation Valley Partners, and from KT Venture Group. Ben Franklin Technology Partners and 21 Ventures also participated in the round through debt conversion agreements.
Battelle said that biotechnology executive Edward Erickson and Battelle partner Tracy Warren have joined BioNanomatrix’ board of directors.
Warren said that the BioNanomatrix technology, which is based on nanochips that are compatible with off-the-shelf optics, can be used to “significantly reduce the time, complexity and cost dynamics of sequencing the genome and carrying out genetic analyses.”
In September, BioNanomatrix and partner Complete Genomics were awarded an $8.8 million grant from the US National Institute of Standards and Technology to develop a high-throughput sequencing technology that they said will be able to sequence a human genome in eight hours for less than $100.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.